{"id":886,"date":"2026-02-13T00:09:57","date_gmt":"2026-02-13T08:09:57","guid":{"rendered":"https:\/\/www.getasecondopinion.ai\/blog\/?p=886"},"modified":"2026-02-13T00:09:58","modified_gmt":"2026-02-13T08:09:58","slug":"centanafadine-and-a-new-chapter-for-adhd-treatment","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/centanafadine-and-a-new-chapter-for-adhd-treatment\/","title":{"rendered":"Centanafadine and a new chapter for ADHD treatment"},"content":{"rendered":"\n

ADHD treatments have long relied on stimulants like methylphenidate and amphetamines, plus a handful of nonstimulant options. Centanafadine is a different kind of medicine that\u2019s drawing attention because recent clinical trials show promising results and the U.S. Food and Drug Administration has given its application an accelerated review. If approved, centanafadine would be the first in a new class of once\u2011daily oral drugs that target three brain chemical transporters at once – norepinephrine, dopamine, and serotonin – which may help with attention, impulsivity, and mood symptoms.<\/p>\n\n\n\n

What centanafadine is and how it works<\/strong><\/h3>\n\n\n\n

What it does.<\/strong> Centanafadine is an investigational extended\u2011release capsule designed to block the reuptake of norepinephrine, dopamine, and serotonin. Blocking reuptake means these neurotransmitters stay active in the spaces between brain cells a bit longer, which can improve focus and reduce impulsive behavior. Because it affects three systems, researchers call it a norepinephrine\u2011dopamine\u2011serotonin reuptake inhibitor, or NDSRI.<\/p>\n\n\n\n

Why that matters.<\/strong> Most current ADHD stimulants primarily boost dopamine and norepinephrine. Adding serotonin modulation could help with emotional regulation and anxiety symptoms that often come with ADHD, though that idea still needs confirmation in broader real\u2011world use.<\/p>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
\n
See Your Ranked Personalized Treatments<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n

The clinical trial evidence so far<\/strong><\/h3>\n\n\n\n

Otsuka, the company developing centanafadine, submitted a New Drug Application (NDA) to the FDA supported by four pivotal Phase 3 trials that enrolled children, adolescents, and adults. These were randomized, double\u2011blind, placebo\u2011controlled studies – the gold standard for testing a drug\u2019s effect. Across the trials, centanafadine showed statistically significant improvements in standard ADHD symptom scales compared with placebo, and the most common side effects were generally mild to moderate (decreased appetite, nausea, rash, fatigue, abdominal pain, somnolence, and headache).<\/p>\n\n\n\n

Key trial highlights in plain language<\/strong><\/p>\n\n\n\n